We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

GCSF Adjunct Therapy for Biliary Atresia (BA_GCSF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03395028
Recruitment Status : Completed
First Posted : January 9, 2018
Last Update Posted : February 17, 2020
T. Rose Clinical, Inc., United States
Children's National Health System
Big Leap Research, Vietnam
Information provided by (Responsible Party):
Holterman, Ai-Xuan, M.D.

Brief Summary:
The Investigators propose to test the hypothesis that GCSF therapy enhances the clinical outcome of Kasai operated Biliary Atresia (BA) patients. In this study, Investigators will conduct a dose determination for GCSF use in post Kasai subjects to support a future phase 2 efficacy study. The first 3 post Kasai BA subjects with liver biopsy-confirmed BA will be given 5 ug/kg/d of GCSF in 3 daily subcutaneous doses starting on post Kasai day 3. A second group of 3 subjects will be assigned to the 10 ug/Kg/d dose after the 5ug/kg/d dose has been proven to be safe. The levels of circulating hematopoietic stem cells and a 1-month safety profile will be analyzed.

Condition or disease Intervention/treatment Phase
Biliary Atresia Drug: Granulocyte Colony-Stimulating Factor Early Phase 1

Detailed Description:

In BA, neonatal fibrous obliteration of the biliary tract obstructs biliary drainage and promotes biliary fibrosis. BA is the leading cause of pediatric chronic end-stage liver disease and pediatric liver transplantation. Relief of cholestasis by the Kasai portoenterostomy is only partly successful with continued progression of fibrosis to hepatic insufficiency and, for long term survival, with eventual need for liver transplantation in the majority of the patients. In animal models of liver injury, GCSF enhances hematopoietic stem cell HSC mobilization and engraftment in the liver with associated improved liver repair response and attenuated hepatic necrosis and fibrosis. Randomized controlled trials of GCSF intervention for chronic liver failure in adult patients with acute hepatic decompensation showed improved short-term survival and hepatic indices such the model for end-stage liver disease (MELD) scores.

The Investigators propose that post Kasai GCSF therapy attenuates biliary fibrosis and progression to cirrhosis. The objectives are meant to demonstrate that Kasai-GCSF sequential therapy improves biliary drainage, and delays the progression of hepatic insufficiency. Toward this goal, Investigators will first evaluate in post Kasai subjects the maximum tolerated dose of GCSF in mobilizing circulating CD34+ hematopoietic stem cells, with the limiting dose based on GCSF-related severe adverse effects. A one-month safety of GCSF will be tested with the 2 standard doses of 5 ug/kg/d and 10 ug/kg/d.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Dose determination for GCSF
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia
Actual Study Start Date : January 15, 2018
Actual Primary Completion Date : January 31, 2020
Actual Study Completion Date : January 31, 2020

Intervention Details:
  • Drug: Granulocyte Colony-Stimulating Factor
    G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
    Other Name: Filgrastim

Primary Outcome Measures :
  1. Dose determination GCSF [ Time Frame: 13 months ]
    To determine the maximum tolerated dose of GCSF based on GCSF dose limiting toxicity and the extent of peripheral blood stem cell mobilization as measured by increases in CD34+cells with upper levels limited by white blood cells (WBCs) less than 50,000 per microliter (mcL) of blood.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Weeks to 180 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Completed the preliminary work up for cholestasis with suspected or inconclusive diagnosis of BA
  2. Gestational Age > 36wks
  3. Weight > 2 Kg
  4. Age >-2 weeks-<180 days at diagnosis
  5. Serum Direct Bilirubin > 2 mg/dL GGT > 100 U/L
  6. Kasai operated patients for Type 3 or 4 anatomy of BA
  7. Cholangiogram/porta hepatis findings diagnostic of BA
  8. Liver biopsy supporting BA diagnosis

Exclusion Criteria:

  1. Having access to liver transplantation for immediate Kasai failure
  2. Prior Kasai patients
  3. Major cardiac, renal, CNS malformations with poor prognosis
  4. Intracranial hemorrhage
  5. History of recent TPN use within the last 2 weeks of surgery
  6. GI tract obstruction
  7. Laparoscopic Kasai repair

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03395028

Layout table for location information
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
National Childrens Hospital
Hanoi, Vietnam
Sponsors and Collaborators
Holterman, Ai-Xuan, M.D.
T. Rose Clinical, Inc., United States
Children's National Health System
Big Leap Research, Vietnam
Layout table for investigator information
Principal Investigator: Evan P Nadler, MD Children's National Research Institute
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Holterman, Ai-Xuan, M.D.
ClinicalTrials.gov Identifier: NCT03395028    
Other Study ID Numbers: CR00005169
IND 119679-0007 ( Other Identifier: Food and Drug Administration )
First Posted: January 9, 2018    Key Record Dates
Last Update Posted: February 17, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Holterman, Ai-Xuan, M.D.:
Biliary Atresia
Granulocyte Colony Stimulating Factor
Additional relevant MeSH terms:
Layout table for MeSH terms
Biliary Atresia
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Digestive System Abnormalities
Congenital Abnormalities
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs